Table 2.

Qualitative summary of the network meta-analysis

Population	Outcome	Empagliflozin	Dapagliflozin	Canagliflozin	Sotagliflozin	Ertugliflozin	TSA
DM	Death	Lowest risk	Lower risk	Lower risk	Without significance	Without significance	Non-conclusion
	CV death	Without significance	Lowest risk	Without significance	Without significance	Without significance	Non-conclusion
	CV death or HHF	Lower risk	Lower risk	Lower risk	Lower risk	Without significance	Conclusion*
	Kidney function progression	Lower risk	Lowest risk	Lower risk	Without significance	Without significance	Conclusion*
	AKI	Lower risk	Lower risk	Lower risk without significance	Without significance	Without significance	Conclusion*
	Ketoacidosis	Without significance	Without significance	Higher risk without significance	Without significance	Higher risk without significance
	Lower limb amputation	Without significance	Without significance	Highest risk	Without significance	Higher risk without significance
	UTI	Without significance	Without significance	Higher risk without significance	Without significance	Highest risk
	Mycotic genital infections	Higher risk	Highest risk	Higher risk	Higher risk	Higher risk
	Hypoglycemia	Without significance	Lower risk without significance	Without significance	Without significance	Without significance
	Bone fracture	Without significance	Without significance	Higher risk without significance	Without significance	Without significance
Non-DM	Death	Higher risk than Dapagliflozin without significant difference	Lower risk	NR	NR	NR	Non-conclusion
	CV death	Lower risk	Lower risk	NR	NR	NR	Non-conclusion
	CV death or HHF	Lower risk	Lower risk	NR	NR	NR	Conclusion*
	Kidney function progression	Lower risk	Lower risk	NR	NR	NR	Conclusion*
	AKI	Lower risk	Lower risk	NR	NR	NR	Conclusion*
	Lower limbs amputation	Without significance	Without significance	NR	NR	NR
HF	MACEs		Without significance	Lower risk without significance	Lowest risk	Without significance	Non-conclusion
	CV death or HHF	Lower risk	Lower risk	Without significance	Lowest risk	Without significance	Conclusion*
Non-HF	MACEs		Lower risk without significance	Lowest risk		Without significance	Non-conclusion
	CV death or HHF	Lower risk	Lower risk	Lowest risk		Without significance	Non-conclusion
CKD	Kidney-specific composite outcome	Lowest risk	Lower risk	Lower risk
	CV death or HHF	Lower risk	Lowest risk				Conclusion*
	Renal-specific composite outcome	Lowest risk		Lower risk without significance
Non-CKD	Kidney- specific composite outcome	Lowest risk
	CV death or HHF	Lowest risk		Lower risk			Conclusion*

AKI acute kidney injury, CKD chronic kidney disease, CV cardiovascular, HF heart failure, HHF hospitalization for heart failure, MACEs major adverse cardiac events, TSA trial sequential analysis, UTI urinary tract infection. *Conclusion: TSA showed that the cumulative z curve reached the benefit boundary with attaining required information size